Key result
A doubling of plasma omentin-1 levels was associated with a higher risk of incident stroke, but not myocardial infarction.
Why the study?
Are higher plasma omentin-1 levels associated with incident myocardial infarction and stroke in a general population cohort?
Cohort (n=2,084)
Are higher plasma omentin-1 levels associated with incident myocardial infarction and stroke in a general population cohort?
Higher plasma omentin-1 concentrations are associated with an increased risk of incident stroke, particularly in metabolically healthy individuals, but not with myocardial infarction.
Answers are grounded in this paper and cite their sources.
May signal higher stroke risk but should not yet alter practice; leaves open causal role and biomarker utility.
BACKGROUND AND AIMS: The recently identified adipokine omentin-1 is inversely associated with body fatness, metabolic syndrome and cardiovascular disease (CVD) in cross-sectional analyses. However, prospective data on the association between plasma omentin-1 levels and future risk of CVD are lacking. The aim of the study was to investigate the relationship between omentin-1 and incident myocardial infarction (MI) and stroke. METHODS: We conducted a case-cohort study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort comprising a subsample of 2084 participants, including 50 CVD cases and 350 external incident CVD cases (mean follow-up of 8.2 ± 1.6 years). Prentice modified Cox regression adjusted for established CVD risk factors was used to estimate associations between omentin-1 and risk of MI and stroke, interactions were tested with cross-product terms. RESULTS: After multivariable adjustment, omentin-1 was not significantly associated with risk of MI (HR per doubling omentin-1:1.17; 95%-CI:0.79-1.72; p = 0.43), but with higher risk of stroke (HR per doubling omentin-1:2.22; 95%-CI:1.52-3.22; p < 0.0001). In subgroup analyses, associations between omentin-1 and stroke risk were generally stronger in lower versus higher CVD risk groups. For example, risk of stroke was stronger in participants without metabolic syndrome (HR per doubling omentin-1:2.58; 95%-CI:1.64-4.07; p < 0.0001) compared to those with metabolic syndrome (HR per doubling omentin-1:1.21; 95%-CI:0.59-2.50; p = 0.60) (p for interaction = 0.05). Similar interactions were observed when participants were classified in low or high risk groups according to waist circumference, triglyceride, hsCRP or adiponectin levels. CONCLUSIONS: Omentin-1 concentrations may be related to increased stroke risk. This association is stronger in metabolically healthy individuals.
No takes yet. Share an insight, caveat, or question.
Menzel et al. (2016) conducted a cohort in Cardiovascular disease (n=2,084). Plasma omentin-1 vs. Lower omentin-1 levels was evaluated on Incident stroke (HR 2.22, 95% CI 1.52-3.22, p=< 0.0001). A doubling of plasma omentin-1 levels was associated with a higher risk of incident stroke, but not myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: